Connect with us

European Commission

Commission clears acquisition of BPS by Advent and Warburg Pincus

SHARE:

Published

8 months ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The European Commission has approved, under the EU Merger Regulation, the acquisition of joint control of Baxter Pharmaceutical Solutions LLC of the US and Baxter Oncology GmbH of Germany ('BPS') by Advent International Corporation and affiliated funds (‘Advent') and Warburg Pincus LLC and affiliated funds (‘Warburg Pincus'), both of the US.

BPS provides contract development and manufacturing organization services for finished dose pharmaceuticals. Advent is a private equity investor focusing on the acquisition of equity stakes and the management of investment funds in various sectors, including healthcare. Warburg Pincus is a global private equity firm active in a variety of sectors, including healthcare.

The Commission concluded that the proposed acquisition would raise no competition concerns, given the companies' limited combined market position and the limited vertical relationships resulting from the proposed transaction. The transaction was examined under the simplified merger review procedure.

More information is available on the Commission's competition website, in the public case register under the case number M.11168.

Share this article:

Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter.
Advertisement

Trending